Shares of Novavax Inc (NVAX) surged 6.63% in Wednesday's intraday trading session, as the biotechnology company announced the sale of its manufacturing facility in Bohumil, Czech Republic, to Danish pharmaceutical giant Novo Nordisk for $200 million.
According to reports, Novavax intends to utilize the proceeds from this divestment to fund its vaccine pipeline development. The sale comes as Novavax aims to focus its resources on its core vaccine business and streamline operations following the COVID-19 pandemic.
Investors reacted positively to the news, viewing the sale as a strategic move that will provide Novavax with additional capital to advance its promising vaccine candidates. The company's decision to divest a non-core asset was seen as a step towards strengthening its financial position and concentrating on its core competencies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.